ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced the presentation of data ... average is $36.66 and its 200 …
In several ways, Acadia Pharmaceuticals (NASDAQ: ACAD) crushed it in 2017 ... Despite all of this good news, Acadia stock finished the year up only 4%. Acadia CEO Stephen Davis didn't mention the underwhelming performance of the …
especially with off-label usage and label expansion all very big parts of the ACAD stock story going forward. If Acadia struggles out the gate with Nuplazid, or encounters typical setbacks that one should expect from a first-time …
The biggest risk facing ACAD stock right now is whether it secures a marketing partner. ACAD looks ready to market Nuplazid alone, which will cause pressure on ACAD stock over the next year. Long term, the promise of Nuplazid will …
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here. ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD announced the …
The big question is whether big pharma values ACAD stock the same way that Acadia Pharmaceuticals management does. I think that’s the big disconnect right now. Acadia Pharmaceuticals has a market capitalization over $5 billion, …
ACADIA Pharmaceuticals Inc. ACAD is scheduled to report second-quarter 2016 results on Aug 4 after the market closes. In the last reported quarter, ACADIA had posted a negative earnings surprise of -12.5%. Let’s see how things are …
Acadia Pharmaceuticals (NASDAQ:ACAD) recently announced full enrollment in the latest phase 3 clinical trial for it's lead drug candidate Pimavanserin for treatment of Parkinson's disease psychosis (PDP). Based on past movements in the …